Vectura Group (LON:VEC)‘s stock had its “hold” rating restated by stock analysts at Peel Hunt in a research note issued on Monday.
A number of other research firms also recently issued reports on VEC. Numis Securities reaffirmed a “buy” rating on shares of Vectura Group in a report on Wednesday, September 12th. Shore Capital reaffirmed a “hold” rating on shares of Vectura Group in a report on Thursday, November 8th. Citigroup reaffirmed a “buy” rating and set a GBX 155 ($2.03) price objective on shares of Vectura Group in a report on Monday, September 10th. Royal Bank of Canada cut their price objective on shares of Vectura Group from GBX 92 ($1.20) to GBX 88 ($1.15) and set a “sector performer” rating on the stock in a report on Wednesday, September 12th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Vectura Group in a report on Wednesday, September 12th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Vectura Group presently has a consensus rating of “Buy” and an average target price of GBX 124.88 ($1.63).
VEC opened at GBX 77.60 ($1.01) on Monday. Vectura Group has a 1 year low of GBX 70 ($0.91) and a 1 year high of GBX 166.97 ($2.18).
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.
Featured Article: Buyback For Investors Defined
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.